Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplastic Large Cell Lymphoma (ALCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Acimtamig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, angioimmunoblastic T cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A.
Affimed, a subsidiary of Affimed NV, is a pharmaceutical company that discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed mycosis fungoides, CD30-positive T cell lymphoma and Hodgkin’s lymphoma; AFM24, against solid tumors; AFM-26, targeting B-cell maturation antigen to treat multiple myeloma. It generates multi-specific antibodies to kill tumor cells and treat cancers through its ROCK platform technology. The company works in partnership with Amphivena Therapeutics Inc, Merck & Co Inc, Genentech Inc, AbCheck SRO and other companies to advance its pipeline. Affimed is headquartered in Mannheim, Baden-Wurttemberg, Germany
For a complete picture of Acimtamig’s drug-specific PTSR and LoA scores, buy the report here.